Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

antibody–drug conjugate

11th Jun 2025

Plain language summary: Examining how loncastuximab tesirine performs after CAR T-cell treatment for diffuse large B-cell lymphoma in everyday practice

11th Jun 2025

Real-world results of sequential loncastuximab and CAR T-cell therapy in large B-cell lymphoma: plain language summary

20th May 2025

Plain language summary: EVOKE-01 study comparing sacituzumab govitecan vs docetaxel for lung cancer

17th Mar 2025

A plain language summary of the TROPiCS-02 study: impact of sacituzumab govitecan on quality of life in patients with HR-positive/HER2-negative breast cancer

15th Nov 2024

Loncastuximab tesirine for treated diffuse large B-Cell lymphoma: LOTIS-2 study

16th Sep 2024

Plain language summary of the ASCENT Study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

1st Sep 2021

A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy